Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A prospective study

Anticancer Research

Volumn 17, Issue 5 B, 1997, Pages 3799-3802

  Tsavaris, Nicolas ^a   Primikirios, Nicolaos ^b   Mylonakis, Nicolas ^c   Varouchakis, George ^b   Dosios, Theodosios ^a   Pavlidis, Nicolaos ^d   Skarlos, Dimosthenis ^e   Tasopoulos, Thomas ^a   Dritsas, John ^a   Kosmidis, Paris ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b SISMANOGLIO HOSPITAL   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

^e AGII ANARGIRI CANCER HOSPITAL   (Greece)

Author keywords

Chemotherapy; Cisplatin; Doxorubicin; Malignant mesothelioma; Vinblastine

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOXICITY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT MESOTHELIOMA; NAUSEA; NEUTROPENIA; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; RETROSPECTIVE STUDIES; VINBLASTINE;

EID: 0031467590     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pollock RE, Karnell LH, Menck HR, Winchester DP: The National Cancer Data Base report on soft tissue sarcoma. Cancer 78: 2247-2257, 1996.
2. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C. Randmized phase II trial of Cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B J Clin Oncol 11: 1559-1565, 1993.
3. Rossof AH: Chemotherapy in the management of mesothelioma. In Kitte CF: Mesothelioma diagnosis and management. Year book medical Publishers Inc: Chicago, London, 1987.
4. Yap BS, Benjamin RS, Burgess MA, Bodey GP: The value of Adriamycin in the treatment of diffuse malignant pleural mesothelioma. Cancer 42: 1692-1696, 1978.
5. Tsavaris N, Mylonakis N, Karvounis N, Briasoulis E, Skarlos D, Pavlidis N, Stamatelos G, Kosmidis P: Combination chemotherapy with cisplatin-vinblastin in malignant mesothelioma. Lung Cancer 11: 299-303, 1994.
6. Planting AS, Schellens JH, Goey SH, Van der Burg ME, De Boer-Dennert M, Stoter G, Vermweij J: Weekly high dose cisplatin in malignant pleural mesothelioma. Ann Oncol 5: 373-374, 1994.
7. Mattson K, Giaccone G, Kirkpatrick A, Evrad D, Tammilehto L, Van Breukelen Fj, Planteydt HT, Van Zandwyk N: Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer. Lung Cancer Cooperative Group.J Clin Oncol 10: 824-828, 1993.
8. Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R: Phase II trial of high dose in patients with malignant mesothelioma. Cancer Treat Rep 69: 711-712, 1985.
9. Eisenhauer EA, Evans WK, Murray N, Kocha W, Wierzbicki R, Wilson K: A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. Invest New Drugs 6: 327-329, 1988.
10. Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Militello L: A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Ongology Group Study. Invest New Drugs 6: 223-226, 1988.
11. Miller AB, Hoogstraten B, Staquet M, Wrinkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
12. Cantwell BM, Franks CR, Harris AL: A phas the platinum analogues JM8 and JM9 in malignant pleural mesothelioma. Cancer Chemother Pharmacol 18: 286-288, 1986.
13. Magri MD, Foladore A, Veronesi A, Serra C, Nicotra M, Tommassi, M, Granti G, Monfardini S, Bianchi C: Treatment of malignant mesothelioma with epiruhicin and if osfamide: A phase II cooperative study. Annals of Oncology 3: 237-238, 1992.
14. Law MR, Gregor A, Hodson ME, Bloom HJ, Turner-Warwick M Malignant Mesothelioma of the pleural: a study of 52 treated and 64 untreated patients.Thorax 39: 255-259, 1984.
15. Kittle F: Mesothelioma: diagnosis and treatment. First Ed., Yearbook medical publishers inc. Chicago-London 1987.
16. Aisner J, Wiernik P: Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 8: 335-343, 1981.
17. Rusch VW: Trials in malignant mesothelioma. Chest 106: 359S-362S, 1994.
18. Krarup-Hansen A: Phase II trials of malignant mesothelioma: a commentary and update. Lung Cancer 12: 315-318, 1994
19. Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M, Gulisano M, Castagneto B, Scagliotti G, Rinaldi M, Santi L: Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force Phase II study. Cancer 67: 2984-2987, 1991.
20. Henb H, Fiebig H, Schildge J, Arnold H, Hasse J: Phase II study with the combination of cisplayin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 11: 118-120, 1988.
21. Zidar B, Pugh R, Schiffer L, Raju R, Vaidya K, Bloom L, Horne D, Baker L: Treatment of six cases of mesothelioma with doxorubicin and Cisplatin.Cancer 52: 1788-1791, 1983.